Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2266-2268

  Wong, Jonathan P ^a   Nagata, Les P ^a   Christopher, Mary E ^a   Salazar, Andres M ^b   Dale, Roderic M K ^c  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^b Oncovir Inc   (United States)

^c Oligos Etc Inc   (United States)

Author keywords

Nucleic acids; Protection; Viral infections

Indexed keywords

DOUBLE STRANDED RNA; IMMUNOMODULATING AGENT; INTERFERON INDUCING AGENT; LIPOSOME; NUCLEIC ACID; OLIGONUCLEOTIDE; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG EFFICACY; ENCAPSULATION; HUMAN; INFECTION PREVENTION; INFLUENZA VIRUS A; LETHALITY; MORBIDITY; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL RATE; TREATMENT OUTCOME; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

EID: 14844290876     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.037     Document Type: Conference Paper

References (10)

1. N.P. Johnson, and J. Mueller Updating the accounts:global mortality of the 1918-1920 "Spanish" influenza pandemic Bull Hist Med 76 2002 105 115
2. M.M. Madjid, S. Lillibridge, P. Mirhaji, and W. Casscells Influenza as a bioweapon J R Soc Med 96 2003 345 346
3. Centers for Disease Control Prevention and control of influenza: recommendations of the immunization practices advisory committee Morb Mortal Wkly Rep 41 RR-9 1992 1 5
4. R.B. Bleshe, M. Hall-Smith, C.B. Hall, and R. Betts Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance J Infect Dis 159 1989 430 435
5. H.B. Levy, G. Baer, S. Baron, C.E. Buckler, C.J. Gibbs, and M.J. Iadorola A modified polyriboinosinic-polyribocyticylic acid complex that induces interferon in monkeys J Infect Dis 132 1975 434 439
6. J.P. Wong, E.G. Saravolac, D. Sabuda, H.B. Levy, and M. Kende Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice Antimicrob Agents Chemother 39 1995 2574 2576
7. D.M. Klinman Use of CpG oligodeoxynucleotides as immunoprotective agents Expert Opin Biol Ther 4 2004 937 946
8. W.M. Galbraith, W.C. Hobson, P.C. Giclas, P.J. Schechter, and S. Agrawal Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey Antisense Res Dev 4 1994 201 206
9. S.C. Semple, S.K. Klimuk, T.O. Harasym, N.D. Santos, S.M. Ansell, and K.F. Wong Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structure Biochim Biophys Acta 78005 2000 1 15
10. J.P. Wong, H. Yang, L. Nagata, M. Kende, H. Levy, and G. Schnell Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC Vaccine 17 1999 1788 1795